Auristone

Auristone is a biotechnology company specializing in epigenomic profiling to help cancer patients determine their likely response to immunotherapy drugs. The company's primary focus is on advanced gastric cancer patients, providing a specialized test that leverages next-generation sequencing (NGS) to deliver actionable insights for physicians. Auristone operates in the healthcare and biotechnology market, targeting oncologists and healthcare providers who treat cancer patients. The business model revolves around selling its proprietary epigenetic profiling tests, which can be bundled with other genomic tests to offer comprehensive diagnostic solutions. Revenue is generated through the sale of these tests and potential co-development partnerships for new drug targets identified through their research.

Keywords: epigenomic profiling, immunotherapy, gastric cancer, biotechnology, NGS, oncology, diagnostic tests, healthcare, biomarkers, drug targets.